key: cord-1054213-9hkh9871
authors: Lee, Yeong-Geun; Won Kang, Kyung; Hong, Woojae; Hwa Kim, Yeon; Taek Oh, Jen; Won Park, Dae; Ko, Minsung; Bai, Yun-Feng; Seo, Young-Jin; Lee, Sang-Myeong; Kim, Hyunggun; Chan Kang, Se
title: Potent antiviral activity of Agrimonia pilosa, Galla rhois, and their components against SARS-CoV-2
date: 2021-07-23
journal: Bioorg Med Chem
DOI: 10.1016/j.bmc.2021.116329
sha: 5ba7413340eaae961bc3b5768e348eeaf098a974
doc_id: 1054213
cord_uid: 9hkh9871

Agrimonia pilosa (AP), Galla rhois (RG), and their mixture (APRG64) strongly inhibited SARS-CoV-2 by interfering with multiple steps of the viral life cycle including viral entry and replication. Furthermore, among 12 components identified in APRG64, three displayed strong antiviral activity, ursolic acid (1), quercetin (7), and 1,2,3,4,6-penta-O-galloyl-β-D-glucose (12). Molecular docking analysis showed these components to bind potently to the spike receptor-binding-domain (RBD) of the SARS-CoV-2 and its variant B.1.1.7. Taken together, these findings indicate APRG64 as a potent drug candidate to treat SARS-CoV-2 and its variants.

(SARS-CoV-2) emerged in China in December 2019, it has spread rapidly worldwide. The World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) a global pandemic on March 11, 2020 (Shan et al., 2020) . Despite diverse efforts to prevent and control its spread, SARS-CoV-2 is ongoing, and the mortality rate is approximately 2.22% (as of March 5, 2021; WHO, 2021) . Due to the severe threat this poses, development of antiviral drugs targeting the virus is a top priority. Several candidates for the treatment of are being developed. In recent studies, remdesivir and chloroquine effectively suppressed the replication of SARS-CoV-2 in vitro and in pre-clinical studies with murine and nonhuman primate models (Wang et al., 2020) . Although these drug repositioning compounds are being tested clinically for their inhibitory effects on replication of SARS-CoV-2 (Grein et al., 2020) , strictly controlled trials have not been completed. Despite the high in vitro antiviral potency of remdesivir against SARS-CoV-2 and some optimistic outcomes in clinical trials (Holshue et al., 2020) , uncertainties regarding its side effects (nausea, vomiting, rectal hemorrhage, and hepatic toxicity) and clinical efficacy remain major concerns (Jean et al., 2020) . In addition, another antiviral compound, chloroquine, is not recommended due to safety concerns (side effects on hematologic, hepatic, and renal systems and QTc prolongation with ventricular dysrhythmia) (Cortegiani et al., 2020) .

Agrimonia pilosa (AP; Rosaceae), commonly known as hairy agrimony, is distributed widely and cultivated in Korea and China, and its aerial parts have been used as an antiviral and for treating hematochezia, traumatic injury, diarrhea, and leukorrhea in Oriental medicine (Min et al., 2001; Nguyen et al., 2017; Shin et al., 2010) . Galla rhois (RG) is the gall caused by the Chinese aphid Schlechtendalia chinensis (Bell) on Rhus chinensis leaves (Anacardiaceae) and has been used in Oriental medicine for treatment of excessive sweating, persistent cough, and diarrhea (Yim et al., 2016; Choi et al., 2014; Djakpo et al., 2010) . In our previous work, a 50% EtOH aqueous extract mixture of AP and RG in a 6:4 ratio (APRG64) was optimal to exert maximum biological activities without significant pharmacological toxicity on cardiovascular, central nervous, and respiratory systems (Kwon et al., 2019; Park et al., 2020) .

Therefore, we hypothesized that AP, RG, and APRG64 will display antiviral activity against SARS-CoV-2. Furthermore, because the emergence of novel variants such as VUI-202012/01 (United Kingdom) and 501.V2 (South Africa) continuously raises concerns for public health, the development of effective antiviral drugs for SARS-CoV-2 and its variants is needed (Loconsole et al., 2021; Peñarrubia et al., 2021) . Thus, in the present study, the efficacy of APRG64 for inhibiting the replication of SARS-CoV-2 by interfering with multiple steps of the viral life cycle, including viral entry, was evaluated. In addition, to confirm the possibility as potential therapeutic candidates against novel variant VUI-202012/01, molecular docking of major components of APRG64 was performed at the spike receptor-binding-domain (RBD) of SARS-CoV-2 and its variant B.1.1.7.

The resins used for column chromatography (c.c.) and TLC analysis were described previously (Lee et al., 2019a) . Optical rotation, NMR (600 MHz), IR, FABMS, and melting point measurements were performed according to previously reported studies (Lee et al., 2019b) . Compounds 2-10 were purchased from Sigma-Aldrich (St. Louis, MO, USA).

Dried aerial parts of AP and RG were provided by BioKorea Co., Ltd (Seoul, Korea).

The plants were identified and authenticated based on macroscopic and microscopic characteristics by Professor Se Chan Kang, Kyung Hee University (Yongin, Korea).

Guaranteed samples (BMRI-AP-1601 and BMRI-RG-1602) were deposited in the Laboratory of Natural Medicine Resources in BioMedical Research Institute, Kyung Hee University. The dried aerial parts of AP (500 g) and RG (500 g) were extracted twice with 50% aqueous EtOH (7 L) at room temperature. Each concentrate was divided into EtOAc and H 2 O fractions. After repeated separation of SiO 2 and octadecyl SiO 2 (ODS), c.c. of the EtOAc fraction of AP resulted in isolation of ursolic acid (1). In addition, repeated c.c. of the EtOAc fraction of RG resulted in isolation of ethyl gallate (11) and 1,2,3,4,6-penta-O-galloyl-β-D-glucose (12). When comparing their NMR and MS values with those reported in the literature, compounds 1, 11, and 12 were confirmed as ursolic acid (Seebacher et al., 2003) , ethyl gallate (Zhang et al., 2014) , and 1,2,3,4,6-penta-O-galloyl-β-D-glucose (Piao et al., 2008) Hz, H-3), 5.48 (1H, br. s, H-12); 13 C NMR (150 MHz, δ C , pyridine-d 5 ) 15.5 (C-25), 16.4 (C-24), 17.2 (C-26), 17.3 (C-29), 18.6 (C-6), 21.2 (C-30), 23.4 (C-11), 23.7 (C-27), 24.7 (C-16), 27.9 (C-2), 28.5 (C23), 28.6 (C-15), 30.8 (C-21), 33.4 (C-7), 37.1 (C-22), 37.2 (C-10), 38.8 H-1), 6.89 (2H, s, H-3-G-2,6), 6.94 (2H, s, H-2-G-2,6), 6.97 (2H, s, H-4-G-2,6), 7.04 (2H, s, H-1-G-2,6), 7.10 (2H, s, H-6-G-2,6); 13 C NMR (150 MHz, δ C , CD 3 OD) 63.1 (C-6), 69.8 (C-4), 72.2 (C-2), 74.1 (C-3), 74.4 (C-5), 93.8 (C-1), 110.3 (C-6-G-2,6), 110.4 (C-3-G-2,6), 110.4 (C-2-G-2,6), 110.5 (C-4-G-2,6), 110.6 (C-1-G-2,6), 119.7 (C-1-G-1), 120.2 (C-2-G-1), 120.4 (C-4-G-1), 120.4 (C-3-G-1), 121.1 (C-6-G-1), 140.0 (C-6-G-3,5), 140.1 (C-3-G-3,5), 140.4 (C-2-G-3,5), 140.4 (C-4-G-3,5), 140.8 (C-1-G-3,5), 146.3 (C-3-G-4), 146.4 (C-2-G-4), 146.5 (C-4-G-4), 146.5 (C-6-G-4), 146.6 (C-1-G-4), 166.2 (C-1-G-7), 166.9 (C-4-G-7), 167.0 (C-2-G-7), 167.3 (C-3-G-7), 168.0 (C-6-G-7).

SARS-CoV-2 (NCCP43326) was provided kindly by the National Culture Collection for Pathogens. Amplification and titration of SARS-CoV-2 were performed on Vero cells as previously described (Liu et al., 2016) . Vero cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with penicillin/streptomycin and 10% fetal bovine serum (FBS). To infect the cells with SARS-CoV-2, Vero cells were incubated for 1 h with the virus in the presence of Eagle's Minimum Essential Medium (MEM) or DMEM containing 0.3% bovine serum albumin (BSA).

The samples were diluted serially from 1/40 to 1/640 with serum-free medium. Vero cells were infected with 50 or 100 plaque-forming units (PFUs) of SARS-CoV-2 and treated with the diluted samples for 1 h at 37°C in 5% CO 2 . After washing with PBS twice to remove unbound viruses, the cells were overlaid with 0.6% agarose diluted in DMEM containing 0.3% BSA. The plates were incubated at 37°C in 5% CO 2 for an additional 3 days. The cells were stained with 0.4% crystal violet (Sigma) dye solution for 10 min and rinsed with PBS three times to remove excess dye. The plaque reduction rate in sample-treated cells was calculated by comparison with untreated cells.

Cell supernatants from virus-infected, sample-treated cells were analyzed for SARS-CoV-2 spike proteins using SARS-CoV-2 spike RBD Nanobody (Cusabio Technology LLC., Houston, TX, USA), according to the manufacturer's instructions. Briefly, Vero E6 cells were infected with SARS-CoV-2 at 0.3 multiplicity of infection (MOI) and treated with sample or cells were infected with SARS-CoV-2 at 0.3 MOI for 1 h, washed three times with PBS, and then treated with sample. After 72 h, cell supernatants were analyzed for binding activity with SARS-CoV-2 using the SARS-CoV-2 spike RBD Nanobody ELISA kit (Cusabio Technology LLC). The cell supernatant was transferred to an antigen (Recombinant Human Novel Coronavirus Spike glycoprotein)-coated assay plate and incubated for 30 min at 37°C in 5% CO 2 . After washing, 100 μL of HRP-conjugate was added to each well and incubated for 30 min at 37°C in 5% CO 2 . After washing, 90 μL of TMB substrate was added to each well and incubated for 20 min in the dark at 37°C in 5% CO 2 . Then, 50 μL of stop solution was added to each well. The optical density of each well was determined within 10 min using a microplate reader set to 450 nm. Once the SARS-CoV-2 spike RBD and ligands were imported into Autodock, all heteroatoms and water molecules were deleted followed and then polar hydrogens and Kollman charges were introduced before the docking process. The SARS-CoV-2 spike RBD (6LZG) and ligands were converted into PDBQT (Protein Data Bank, Partial Charge (Q), and Atom Type (T)) files.

The binding between the SARS-CoV-2 spike RBD and ligands were then examined in Autodock. Blind docking of the ligands was performed to identify the potential primary binding site of the SARS-CoV-2 spike RBD. The entire protein was covered with a grid box dimension of 40×62×62 Å with a spacing of 1 Å for blind docking and standard LGA was employed.

Conformations with high negative binding energy in binding sites were determined and the outcomes were validated through redocking process. below -0.5 indicate that the given structure is unusual while scores below -1.0 infer that the given structure is highly unusual. Ramachandran plot is a torsional angle (phi and psi) map of the residues, frequently used for validation of a 3D protein structure. A given structure is valid if the residues located in the most favored region in the are greater than 90%. Following structural validation of the B.1.1.7 lineage spike protein, the identical molecular docking protocol was performed to determine the binding energy between the active components of APRG64 and the B.1.1.7 lineage spike RBD and compare with the preceding data with the SARS-CoV-2 spike RBD.

Because AP, RG, and APRG64 have clinical potential for diverse diseases, including diarrhea, cough, chills, and hematochezia, as well as antiviral effects, these extracts were analyzed for antiviral activity against SARS-CoV-2. Vero cells pre-treated with AP, RG, APRG64, remdesivir, or chloroquine phosphate for 2 h were infected with SARS-CoV-2. At 72 h post-infection (hpi), reduction of plaque formations was assessed. Notably, all three extracts strongly inhibited the formation of plaques. Even at low concentrations (0.1 and 0.5 µg/mL), their ability to reduce plaque was comparable to that of remdesivir and chloroquine phosphate ( Figure 1A) . Thus, we conclude that AP, RG, and APRG64 suppressed the replication of SARS-CoV-2. Remdesivir (Rem, 5 µM) and chloroquine phosphate (C.P, 10 µM) were used as positive controls. Data are representative of three independent experiments. * p < 0.05; *** p < 0.001, compared with mock-treated cells (Con).

Next, it was investigated whether AP, RG, and APRG64 influence viral entry, which is a key step for SARS-CoV-2 replication. Vero cells were infected with SARS-CoV-2 in the presence or absence of AP, RG, APRG64, remdesivir, or chloroquine phosphate. After 1 h, cells were washed three times with PBS to remove unattached viruses and extracts from cell culture media. Plaque reduction assay revealed that AP, RG, and APRG64 potently inhibited the replication of SARS-CoV-2. Conversely, remdesivir and chloroquine did not show significant antiviral activity compared with AP, RG, and APRG64 ( Figure 1B) . These results strongly support that AP, RG, and APRG64 have potent antiviral activity against SARS-CoV-2 by interfering with viral entry through an antiviral mechanism different from that of remdesivir and chloroquine phosphate.

APRG64 is a mixture of AP and RG, and because its safety in vitro as well as in vivo was proven in our previous study , its active components were investigated.

In repeated c.c. of these plants, ursolic acid (1), ethyl gallate (11), and 1,2,3,4,6-penta-Ogalloyl-β-D-glucose (12) were isolated. Based on LC/MS profiling results of APRG64, one 12) were selected as active components of APRG64 and potential anti-COVID-19 agents ( Figure 2 ). These compounds were reported previously as major components of AP Gao et al., 2015; Zhu et al., 2017; Liu et al., 2016; Feng et al., 2019) and RG (Park et al., 2011; Park et al., 2008) . Compounds 2-10, which were purchased, were analyzed using NMR to evaluate purity. Consequently, purity of all compounds including the isolated compounds (1, 11, and 12) was confirmed to be greater than 97%. 3.4. Antiviral activity of APRG64 active components against SARS-CoV-2

Next, whether secondary metabolites isolated from APRG64 inhibit the replication of SARS-CoV-2 was investigated. Vero cells were infected with SARS-CoV-2 and treated with compounds 1-12, remdesivir, or chloroquine phosphate for 1 h. Cells were washed to eliminate unattached viral particles and compounds. At 72 hpi, the number of plaques was estimated using a plaque assay. As shown in Figure 3A , ursolic (1), quercetin (7), ethyl gallate (11), and 1,2,3,4,6-penta-O-galloyl-β-D-glucose (12) significantly inhibited the formation of plaques at all three concentrations (1, 5, and 25 µg/mL). However, ethyl gallate (11) slightly inhibited the formation of plaques (reduction rate: 21.05% at 25 µg/mL), and ursolic acid (1), quercetin (7), and 1,2,3,4,6-penta-O-galloyl-β-D-glucose (12) exhibited much stronger antiviral activity (reduction rates: 78.35%, 67.19%, and 100%, respectively, at 25 µg/mL) ( Figure 3A ). In particular, 1,2,3,4,6-penta-O-galloyl-β-D-glucose (12) entirely suppressed the formation of plaques at all three concentrations. Furthermore, 1,2,3,4,6-penta-O-galloyl-β-D-glucose (12) displayed potent antiviral activity at much lower concentrations (0.125, 0.25, 0.5 µg/mL; data not shown). Similar results were obtained when cell supernatants were analyzed for SARS-CoV-2 spike protein. As shown in Figure 3B , ursolic acid (1), quercetin (7), and 1,2,3,4,6penta-O-galloyl-β-D-glucose (12) significantly reduced the amount of SARS-CoV-2 spike proteins in cell supernatants ( Figure 3B ). Finally, whether post-treatment with ursolic acid (1), quercetin (7), and 1,2,3,4,6-penta-O-galloyl-β-D-glucose (12) was capable of inhibiting SARS-CoV-2 replication was investigated. Vero cells were infected with SARS-CoV-2 for 1 h, followed by three washes to remove unattached viral particles. Cells then were treated with samples for 72 h. Notably, post-treatment with samples significantly reduced SARS-CoV-2 spike proteins in the supernatants ( Figure 3C) . Collectively, the results strongly support that active components of APRG64, ursolic acid (1), quercetin (7), and 1,2,3,4,6-penta-O-galloylβ-D-glucose (12), inhibit SARS-CoV-2 replication by interfering with viral absorption and post-absorption stages. In previous studies, quercetin (7) was reported to have antiviral activities against HIV, herpes simplex virus type 1 (HSV-1) (Kaul et al., 1985) , hepatitis C virus (HCV) (Rojas et al., 2016) , influenza A virus (IAV) H1N1, and dengue virus 2 (DENV-2) (Cheng et al., 2015 , Chiow et al., 2016 Vaidya et al., 2016) . In addition, Yang et al. reported that 1, 2, 3, 4, has anti-herpes simplex virus activity (Yang et al., 2007) ; however, the anti-SARS-CoV-2 activity remains unknown.

3.5. Structural modeling and validation of B.1.1.7 lineage spike RBD Association between the viral spike RBD and ACE2 proteins on the target cell is a critical step for SARS-CoV-2 to enter the cell. Because APRG64 and its components were shown to interfere with viral absorption (Figures 1 and 3) , the binding of the viral spike RBD onto host cells could be impeded by APRG64 components. infected with SARS-CoV-2 at 0.3 MOI and treated with APRG64, compounds 1, 7, or 12, at 5 or 25 µg/mL for 1 h. After washing three times with PBS, cells were incubated for an additional 72 h. Cell supernatants were analyzed for the SARS-CoV-2 spike proteins using enzyme-linked immunosorbent assay (ELISA). (C) Cells were infected with SARS-CoV-2 at 0.3 MOI for 1 h, followed by washing three times with PBS. Cells were treated with compounds 1, 7, or 12.

After 72 h, cell supernatants were analyzed for SARS-CoV-2 spike protein using ELISA. Data are representative of three independent experiments. * p < 0.05; ** p < 0.01; *** p < 0.001, compared with mock-treated cells (Con).

To test this hypothesis, molecular docking analysis of the viral spike RBD onto the structures of three major antiviral components of APRG64, ursolic acid (1), quercetin (7), and 1,2,3,4,6-penta-O-galloyl-β-D-glucose (12), was performed. Notably, the spike RBD of SARS-CoV-2 continuously undergoes mutations, which hinders the development of efficient vaccines and antiviral drugs. Thus, the binding affinity of APRG components to the SARS-CoV-2 spike RBD as well as its variant B. of the residues to be located in the most favored regions [A, B, L] and 9.4% of the residues in the additionally allowed regions [a, b, l, p] ( Figure 4B ). These data indicate that the generated B.1.1.7. lineage spike RBD structure model is stable stereochemically and accurate. lineage spike RBD with ursolic acid (1), quercetin (7), and 1,2,3,4,6-penta-O-galloyl-β-Dglucose (12) were performed to assess the potential antiviral effects of the active APRG64

components. The binding energy data calculated from the molecular docking analysis are shown in Table 1 . Ursolic acid (1) showed the highest binding energy (-9.5 kcal/mol and -9.0 kcal/mol, respectively) against the SARS-CoV-2 spike RBD and B.1.1.7. lineage spike RBD compared with the other compounds. Notably, quercetin (7) (-8.9 vs. -7.6 kcal/mol) and 1,2,3,4,6-penta-O-galloyl-β-D-glucose (12) (-3.3 vs. -3.1 kcal/mol) showed more stable binding energy when docking with the B.1.1.7. lineage spike RBD compared with docking with the SARS-CoV-2 spike RBD. Figure 5 represents the hydrogen bond interactions of ursolic acid (1), quercetin (7), and 1,2,3,4,6-penta-O-galloyl-β-D-glucose (12) against the SARS-CoV-2 spike RBD and GLY339 of the SARS-CoV-2 spike RBD amino acid residues and formed one hydrogen bond with PHE55 of the B.1.1.7. lineage spike RBD amino acid residues. These data indicate that APRG64 has significant potential to target both SARS-CoV-2 and B.1.1.7. lineage and exert antiviral effects. (7), and 1,2,3,4,6-penta-O-galloyl-β-D-glucose (12).

In the present study, APRG64 and its active components ursolic acid (1), quercetin (7), and 1,2,3,4,6-penta-O-galloyl-β-D-glucose (12) significantly suppressed the replication of SARS-CoV-2. In addition, the three compounds (1, 7, and 12) showed significant binding affinity for SARS-CoV-2 and its variant (VUI-202012/01). Therefore, APRG64 is a novel candidate antiviral agent to treat COVID-19, and further clinical trials are warranted.

Constituents of the aerial parts of Agrimonia pilosa

Inhibition of hepatitis B virus replication by quercetin in human hepatoma cell lines

Evaluation of antiviral activities of Houttuynia cordata Thunb. Extract, quercetin, quercetrin and cinanserin on murine coronavirus and dengue virus infection. Asian Pac

Methyl gallate from Galla rhois successfully controls clinical isolates of Salmonella infection in both in vitro and in vivo systems

A systematic review in the efficacy and safety of chloroquine for the treatment of COVID-19

Two new and four known polyphenolics obtained as new cell-cycle inhibitors from Rubus aleaefolius Poir

Rhus chinensis and Galla chinensis-folklore to modern evidence

Antinociceptive effect of single components isolated from Agrimonia pilosa Ledeb

Determination of six flavonoids in Agrimonia pilosa Ledeb by HPLC

Compassionate use of remdesivir for patients with severe Covid-19

First case of 2019 novel coronavirus in the United States

Treatment options for COVID-19: The reality and challenges

Antiviral effect of flavonoids on human viruses

Triterpenoids from the flower of Campsis grandiflora K. Schum. as human acyl-CoA: cholesterol acyltransferase inhibitors

Identification of coronavirus isolated from a patient in Korea with COVID-19

Anti-viral activity of compounds from Agrimonia pilosa and Galla rhois extract mixture

Flavonoids from Chionanthus retusus (Oleaceae) flowers and their protective effects against glutamate-induced cell toxicity in HT22 cells

6-Methoxyflavonols from the aerial parts of Tetragonia tetragonoides (Pall.) Kuntze and their anti-inflammatory activity

Chemical constituents from Agrimonia pilosa Ledeb. and their chemotaxonomic significance

Genome sequence of a sars-cov-2 vui 202012/01 strain identified from a patient returning from London, England, to the apulia region of Italy

Inhibitory effects of Korean plants on HIV-1 activities

Ellagitannin and flavonoid constituents from Agrimonia pilosa L. with their protein tyrosine phosphatase and acetylcholinesterase inhibitory activities

Tannins and related compounds. Part 5. Isolation and characterization of polygalloylglucoses from Chinese gallotannin

1,2,3,4,6-penta-O-galloyl-β-D-glucose from Galla rhois protects primary rat hepatocytes from necrosis and apoptosis

Evaluation of genetic toxicity, acute and sub-chronic oral toxicity and systemic safety of Agrimonia pilosa and Rhus gall 50% ethanolic extract mixture (APRG64) in vitro and in vivo (rodent and non-rodent animal models)

Involvement of heme oxygenase-1 induction in inhibitory effect of ethyl gallate isolated from Galla rhois on nitric oxide production in RAW 264.7 macrophages

In Response to: Multiple assays in a real-time RT-PCR Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) panel can mitigate the risk of loss of sensitivity by new genomic variants during the COVID-19 outbreak

Antioxidative activity of geranium (Pelargonium inquinans Ait) and its active component, 1, 2, 3, 4, 6-penta-O-galloyl-β-D-glucose

Effect of quercetin on hepatitis C virus life cycle: from viral to host targets

Complete assignments of 1 H and 13 C NMR resonances of oleanolic acid, 18α-oleanolic acid, ursolic acid and their 11-oxo derivatives

Infection with novel coronavirus (SARS-CoV-2) causes pneumonia in Rhesus macaques

Broad-spectrum antiviral effect of Agrimonia pilosa extract on influenza viruses

Effectiveness of periodic treatment of quercetin against influenza a virus H1N1 through modulation of protein expression

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

WHO Coronavirus Disease (COVID-19) Dashboard

The in vitro activity of geraniin and 1,3,4,6-tetra-O-galloyl-β-D-glucose isolated from Phyllanthus urinaria against herpes simplex virus type 1 and type 2 infection

Water extract of Galla rhois with steaming process enhances apoptotic cell death in human colon cancer cells

Structural identification of compounds from Toona sinensis leaves with antioxidant and anticancer activities

Flavonoids from Agrimonia pilosa Ledeb: free radical scavenging and DNA oxidative damage protection activities and analysis of bioactivity-structure relationship based on molecular and electronic structures

The authors declare no conflict of interest.